AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2021
Dec 7, 2021
30604_dirs_2021-12-06_538e7068-1bee-4fcd-b82e-69faad684e3a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-02
Reporting Person: HOMCY CHARLES J (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-02 | Stock Option (right to buy) | $40.03 | A | 55011 | Acquired | 2031-12-01 | Common Stock (55011) | Direct |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 27